October 14, 2020
CRS is the home for experts dedicated to delivery science, including delivery scientists, engineers, clinicians, and technical professionals. CRS members are creating the future of delivery science and technology through fundamental delivery research, development, regulatory science, and clinical translation. Research published in CRS journals and presented during the Annual Meeting & Exposition offers a breadth of scientific knowledge covering new technologies and science in the multi-disciplinary delivery field.
November 9 - 12, 2020
July 23 - 28, 2021
Drug Delivery and Translational Research (DDTR)
Best Paper of the CRS Indian Chapter Special Issue of DDTR: Supersaturated LFCS type III self-emulsifying delivery systems of sorafenib tosylate with improved biopharmaceutical performance: QbD-enabled development and evaluation
Summary: Sorafenib, a first-line drug for advanced liver cancer, exhibits low and inconsistent oral bioavailability due primarily to its poor aqueous solubility, extensive first-pass metabolism and high level drug efflux by P-gp. Administration of sorafenib at high doses, necessary for meaningful therapeutic actions, increases the intensity of associated side effects. Therefore, efforts were undertaken to develop supersaturated Type-III self-emulsifying delivery system (SEDDS) for efficient and safe delivery of sorafenib, capitalizing the ease of preparation, biocompatibility, biodegradability, ability to bypass first-pass metabolism, high drug loading capacity, colloidal stability for long-term storage, and excellent scalability. Promising outcomes in diverse experimental studies corroborate immense potential of the supersaturated Type-III SEDDS in augmenting the chemotherapeutic efficacy of sorafenib while minimizing safety concern.
Inspirational Note from Dr. Jeff Hrkach and Prof. Bob Langer: "From micro to nano: evolution and impact of drug delivery in treating disease"
"As editor-in-chief of DDTR, I am honored to bring such inspiration to the DD community. Many thanks to Bob and Jeff!
Prof. Maria José Alonso, Editor-in-Chief of the Drug Delivery and Translational Research (DDTR) Journal, Past President of the Controlled Release Society
2019 DDTR Best Paper of the Year: Depletion of collagen by losartan to improve tumor accumulation and therapeutic efficacy of photodynamic nanoplatforms
The Best Paper is chosen by the DDTR Editorial Board.
2019 CRS Nanomedicine and Nanoscale Delivery (NND) Best Paper of the Year: Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses
2019 DDTR CRS Oral Drug Delivery Focus Group Paper of the Year Award: Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer
Drug Delivery and Translational Research is a journal published by CRS, providing a unique forum for the scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. The journal is published 6 times a year and will be available online to CRS members as part of their annual dues.
CRS 2021 Annual Meeting
Women In Science
The CRS WIS ran two very successful sessions during the virtual CRS2020 Annual Meeting. Prof. Alonso delivered a very inspirational talk about her career in science that prompted a lively Q&A session where participants could ask their questions live, triggering a collegial and warm atmosphere. We are super proud to announce that this year we had over 150 participants of different nationalities and seniorities, of which a fair amount were men, which we warmly welcome. This allowed a virtual mingling with women CRS past presidents, past Women in Science Award Winners, and peers.
Thank you all for making these sessions an outstanding success and especially thanks to Prof. Alonso for willingly sharing her legacy in science and her path to get there. We are looking forward to welcoming your ideas and experiences and to keep us all engaged. Please contact Ruth Schmid with any questions. We also hope to see you face-to-face in Montreal in 2021!